Apellis Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $212,528 | $196,830 | $199,685 | $172,325 |
Gross Profit | 171,672 | 163,273 | 176,136 | 151,672 |
EBITDA | -43,864 | -27,735 | -58,842 | |
EBIT | -44,485 | -28,184 | -59,286 | |
Net Income | -36,353 | -57,445 | -37,657 | -66,423 |
Net Change In Cash | 212,528 | 196,830 | 199,685 | 172,325 |
Free Cash Flow | 19,340 | 34,096 | -8,429 | -133,276 |
Cash | 411,290 | 396,864 | 361,426 | 327,026 |
Basic Shares | 124,495 | 123,904 | 123,904 | 122,957 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $709,954 | $396,591 | $75,422 | $66,563 |
Gross Profit | 592,231 | 338,081 | 69,786 | 61,363 |
EBITDA | -236,392 | -495,211 | -617,390 | -731,269 |
EBIT | -496,915 | -618,877 | -732,761 | |
Net Income | -197,878 | -528,628 | -652,172 | -746,354 |
Net Change In Cash | 709,954 | 396,591 | 75,422 | 66,563 |
Free Cash Flow | -88,269 | -595,508 | -515,269 | -564,229 |
Cash | 411,290 | 351,185 | 551,801 | 640,192 |
Basic Shares | 123,904 | 118,678 | 106,114 | 84,421 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.29 |
2024-09-30 | -$0.46 |
2024-06-30 | -$0.28 |
2024-03-31 | -$0.42 |
